Age and gender differences in the association between Nt-proBNP and glucometabolic disturbances

Abstract Objectives. Glucometabolic disturbances are associated with myocardial dysfunction. Brain natriuretic peptides (BNP) are used for detecting myocardial dysfunction in clinical practice. However, studies on elderly subjects and gender-specific analyses are sparse. Design. We examined cross-sectional associations between Nt-proBNP and 1) fasting plasma glucose (FPG), and 2) categories of glucometabolic disturbances, in middle-aged and older subjects (1266 men, 526 women), applying multivariate linear regression analysis. Results. FPG was positively correlated with Nt-proBNP among middle-aged men (p = 0.04) and negatively albeit non-significantly (p = 0.1) among middle-aged women. Weaker non-significant correlations were seen among older subjects. Middle-aged men with new-onset and prevalent diabetes had higher Nt-proBNP than the reference group (FPG ≤5.0 mmol/L): 9.53 (p = 0.002) and 8.23 (p = 0.02) vs. 5.71 pmol/L. No differences in Nt-proBNP between categories of glucometabolic disturbance were observed among older men or women. Conclusions. The results indicate an age- and gender difference in the ability of Nt-proBNP to identify myocardial dysfunction in relation to glucometabolic disturbances. Therefore, Nt-proBNP should be used with caution as a general surrogate marker for myocardial dysfunction in this setting.

[1]  V. Gudnason,et al.  Myocardial structure and function by echocardiography in relation to glucometabolic status in elderly subjects from 2 population-based cohorts: a cross-sectional study. , 2010, American heart journal.

[2]  M. Gheorghiade,et al.  The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study. , 2009, Journal of cardiac failure.

[3]  J. Januzzi,et al.  Biology of the natriuretic peptides. , 2008, The American journal of cardiology.

[4]  D. Levy,et al.  Association of Plasma Natriuretic Peptide Levels With Metabolic Risk Factors in Ambulatory Individuals , 2007, Circulation.

[5]  J. Rehfeld,et al.  Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. , 2006, European heart journal.

[6]  M. Connock,et al.  Assessing the diagnostic test accuracy of natriuretic peptides and ECG in the diagnosis of left ventricular systolic dysfunction: a systematic review and meta-analysis. , 2006, The British journal of general practice : the journal of the Royal College of General Practitioners.

[7]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[8]  M. Drazner,et al.  Impact of Body Mass and Body Composition on Circulating Levels of Natriuretic Peptides: Results From the Dallas Heart Study , 2005, Circulation.

[9]  T. Marwick,et al.  Determinants of subclinical diabetic heart disease , 2005, Diabetologia.

[10]  A. DeMaria,et al.  Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function: comparison with tissue Doppler imaging recordings. , 2004, American heart journal.

[11]  P. Collinson,et al.  Evaluation of N-terminal pro-B type natriuretic peptide analysis on the ElecsysTM 1010 and 2010 analysers , 2004, Annals of clinical biochemistry.

[12]  L. Groop,et al.  Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. , 2004, Diabetes care.

[13]  S. Khouri,et al.  A practical approach to the echocardiographic evaluation of diastolic function. , 2004, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[14]  D. Levy,et al.  Impact of Obesity on Plasma Natriuretic Peptide Levels , 2004, Circulation.

[15]  N. Nikitin,et al.  Application of Tissue Doppler Imaging in Cardiology , 2004, Cardiology.

[16]  S. Mudaliar,et al.  Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. , 2003, Diabetes care.

[17]  D. Levy,et al.  Impact of Glucose Intolerance and Insulin Resistance on Cardiac Structure and Function: Sex-Related Differences in the Framingham Heart Study , 2003, Circulation.

[18]  D. Levy,et al.  Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. , 2002, JAMA.

[19]  M. Jensen-Urstad,et al.  Left ventricular diastolic function is related to glucose in a middle‐aged population , 2002, Journal of internal medicine.

[20]  C. Otto,et al.  Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. , 2002, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[21]  K. Eriksson,et al.  Long‐term outcome of the Malmö Preventive Project: mortality and cardiovascular morbidity , 2000, Journal of internal medicine.

[22]  D. Levy,et al.  Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). , 1991, The American journal of cardiology.

[23]  L. Truedsson,et al.  Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate. , 2009, Acta medica Scandinavica.